Zanolimumab, the promising biological agent , represents an significant development in immunotherapy . It functions as a engineered monoclonal , specifically designed to target with the CD4 receptor expressed on T helper immune populations . This binding results to this inhibition in CD4 pathway , effectively modulating the immune response and prov